openPR Logo
Press release

Amyloidosis Pipeline Drugs Assessment: Clinical Trails Analysis, Player Profiles, Collaborations, Key Targets, Geographic Focus, and Data Publications, 2018

05-16-2018 10:00 AM CET | Health & Medicine

Press release from: Precision Business Insights

Amyloidosis Pipeline Drugs

Amyloidosis Pipeline Drugs

Amyloidosis Pipeline Drugs Assessment Overview:

Amyloidosis is a rare disease, which occurs due to deposition of amyloid in organs. It is an abnormal protein, produced in the bone marrow and accumulates at any part of the tissue or organ. Amyloidosis may affect different parts of the body in different people. Amyloidosis affects heart, kidney, liver, spleen and nervous system.

Amyloidosis is diagnosed with the laboratory tests by identifying the abnormality in the protein in blood and urine. Furthermore, imaging techniques and biopsy may be performed to diagnose the disease and presence of amyloidosis.

Treatment is given to relive the symptoms and limit the further production of amyloid. Treatment depends on the type of amyloidosis. Chemotherapeutic agents are used to treat the immunoglobulin light chain amyloidosis and therapies may include autologous blood stem cell transplant. AA amyloidosis is treated by treating underlying condition for example, anti-inflammatory drugs for treating rheumatoid arthritis. For Hereditary amyloidosis, liver transplant may be an option.

A sample of this report is available upon request @
https://www.precisionbusinessinsights.com/market-reports/amyloidosis-pipeline-drugs-assessment/#ulp-4H8Z4LpNMLEuOnnx

Segmentation:
Amyloidosis pipeline drugs are segmented based on route of administration, trial phase, and company
By type, Amyloidosis pipeline drugs are segmented into
• AL Amyloidosis
• AA amyloidosis
• Others
By trial phase, Amyloidosis pipeline drugs are segmented into
• Pre-clinical phase
• Phase-I
• Phase II
• Phase-III
By company, Amyloidosis pipeline drugs are segmented into
• GLAXOSMITHKLINE PLC (U.K.)
• AMGEN INC. (U.S.)
• ALNYLAM PHARMACEUTICALS, INC., (U.S.)
• BELLUS HEALTH INC. (CANADA)
• ARCTURUS THERAPEUTICS (U.S.)
• JOHNSON & JOHNSON SERVICES INC. (U.S.)
• IONIS PHARMACEUTICALS, INC. (U.S.)

To view TOC of this report is available upon request @
https://www.precisionbusinessinsights.com/market-reports/amyloidosis-pipeline-drugs-assessment/#ulp-c654SbFYO64MsOhu


Space Analysis:
• In September 2017 Sanofi and Alnylam Pharmaceuticals reported positive results in late-stage trial of a treatment for hereditary ATTE Amyloidosis patients with polyneuropathy

Need more information about this report @
https://www.precisionbusinessinsights.com/market-reports/amyloidosis-pipeline-drugs-assessment/#ulp-14mlyhjMGhVjZqa3

Report Description:
Amyloidosis Pipeline Drugs Assessment report studies the various therapeutics under clinical development for Amyloidosis treatment along with targets for various drug candidate. The report provides plethora of information pertaining to trail phases, companies involved in the Amyloidosis pipeline drugs development. This report studies the dynamics of the Amyloidosis Pipeline Drugs i.e. drivers, challenges and opportunities which are significantly impacting the product development. The report provides various information pertaining the clinical trials such as designation, grants, patents, and technology among others. Moreover, the report on Amyloidosis pipeline drugs assessment comprehensively presents the geographic location, trial status information along with key players involved in the therapeutics development.

Key Features of the Report:
• Provides the information related to universities and research institutes working in the therapeutics development
• Report comprehensively covers the all active and discontinued studies
• Studies the entire pipeline with special emphasis on companies actively involved in the therapeutics development
• Presents the prominent targets for drug development in each stage of clinical trial
• Provides the in-depth analysis on each drug candidates in the clinical trial phases


Get access to full summary @
https://www.precisionbusinessinsights.com/market-reports/amyloidosis-pipeline-drugs-assessment/

About Precision Business Insights

Precision Business Insights is one of the leading market research and business consulting firm, which follow a holistic approach to solve needs of the clients. We adopt and implement proven research methodologies to achieve better results. We help our clients by providing actionable insights and strategies to make better decisions. We provide consulting, syndicated and customised market research services based on our client needs.

Contact to Precision Business Insights,

Kemp House,
152 – 160 City Road,
London EC1V 2NX

Email: sales@precisionbusinessinsights.com

Toll Free (US): +1-866-598-1553
Website @ https://www.precisionbusinessinsights.com

This release was published on openPR.

Permanent link to this press release:

Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.

You can edit or delete your press release Amyloidosis Pipeline Drugs Assessment: Clinical Trails Analysis, Player Profiles, Collaborations, Key Targets, Geographic Focus, and Data Publications, 2018 here

News-ID: 1050638 • Views:

More Releases from Precision Business Insights

Gaming Controller Market Rising Demand for Gaming Stations and eSports
Gaming Controller Market Rising Demand for Gaming Stations and eSports
According to the Precision Business Insights (PBI), latest report the gaming controller market size was valued at USD 2,382.1 million in 2023, growing at an 8.5% CAGR from 2024 to 2030. The key drivers of the expansion of the global gaming controller include the enhanced gaming experience, technology advancements, consumer preferences and ergonomics, competitive gaming and esports, intuitiveness, and portability of the gaming controllers. View Full Report: https://www.precisionbusinessinsights.com/market-reports/gaming-controller-market
Next Generation Dietary Supplements Market Size, Growth Opportunities 2024-2030
Next Generation Dietary Supplements Market Size, Growth Opportunities 2024-2030
According to Precision Business Insights (PBI), the latest report, the global next-generation dietary supplements market was valued at USD 10,752.3 million in 2023 and is expected to grow at a CAGR of 8.8% from 2024-2030. The primary factors that drive the market are the growing demand for rising consumer knowledge of the various health benefits of Next Generation Dietary Supplements, as well as rising disposable income levels, fuel market expansion
Catamaran Market Increasing Popularity Of Water Sports And Fishing Activities
Catamaran Market Increasing Popularity Of Water Sports And Fishing Activities
According to Precision Business Insights (PBI), the latest report, the catamaran market is valued at USD 1,635.7 million in 2023 and is anticipated to grow a CAGR of 4.9% over the forecast period. The primary factors that drive the market are the growing demand for Catamaran pushes the market to enhance efficiency, minimize time consumption, and reduce post-harvest operating losses. Catamaran are good solutions for reducing high labour costs since
Refrigerated Display Cases Market Size, Share, Growth Trends and Forecast 2024-2030
Refrigerated Display Cases Market Size, Share, Growth Trends and Forecast 2024-2 …
According to Precision Business Insights (PBI), latest report, the refrigerated display cases market was valued at USD 8,248.5 million in 2023 and is expected to grow at a 5.1% CAGR from 2024 to 2030. The primary drivers of the expansion of the global refrigerated display cases market include the increasing demand for frozen food and drinks among urban consumers. In addition, growing awareness about environment sustainability and energy efficiency is

All 5 Releases


More Releases for Amyloidosis

Amyloidosis Market Massive Growth opportunity Ahead
Introduction Amyloidosis is a rare, progressive disease characterized by the abnormal deposition of amyloid proteins in tissues and organs, leading to organ dysfunction and, in severe cases, life-threatening complications. The condition can affect the kidneys, heart, liver, and nervous system, making early detection and effective treatment essential. Historically underdiagnosed, amyloidosis is now gaining visibility due to advances in diagnostic tools, imaging technologies, and therapeutic innovations. In 2024, the global Amyloidosis Market is
Evolving Market Trends In The Transthyretin Amyloidosis Treatment Industry: Inno …
The Transthyretin Amyloidosis Treatment Market Report by The Business Research Company delivers a detailed market assessment, covering size projections from 2025 to 2034. This report explores crucial market trends, major drivers and market segmentation by [key segment categories]. What Is the Expected Transthyretin Amyloidosis Treatment Market Size During the Forecast Period? The market for transthyretin amyloidosis treatments has witnessed significant growth in the past few years. The market, which was valued at
What's Driving the Transthyretin Amyloidosis Treatment Market 2025-2034: Increas …
What Are the Projections for the Size and Growth Rate of the Transthyretin Amyloidosis Treatment Market? The market for transthyretin amyloidosis treatment has seen robust growth in the past years. Its size is forecasted to increase from $5.52 billion in 2024 to $5.95 billion in 2025, with a compound annual growth rate (CAGR) of 7.8%. The surge in the market over the historic period is due to increased disease awareness, progress
Unveiling Transthyretin Amyloidosis Treatment Market 2024
The transthyretin amyloidosis treatment market size has grown strongly in recent years. It will grow from $5.07 billion in 2023 to $5.52 billion in 2024 at a compound annual growth rate (CAGR) of 8.9%. The growth in the historic period can be attributed to increased disease awareness, advancements in diagnostic tools, drug development and approvals, patient advocacy and support, collaboration in research.. The transthyretin amyloidosis treatment market size is
AL Amyloidosis Therapeutics Market - Transforming the landscape of AL amyloidosi …
Newark, New Castle, USA: The "AL Amyloidosis Therapeutics Market" provides a value chain analysis of revenue for the anticipated period from 2023 to 2031. The report will include a full and comprehensive analysis of the business operations of all market leaders in this industry, as well as their in-depth market research, historical market development, and information about their market competitors. AL Amyloidosis Therapeutics Market: https://www.growthplusreports.com/report/al-amyloidosis-therapeutics-market/8684 This latest report researches the industry structure,
Transthyretin Amyloidosis (ATTR) Market 2022 | Detailed Report
The top-notch information research report published by markets and markets is a vital asset that offers qualitative and quantitative factors of the Transthyretin Amyloidosis (ATTR) market. The research study and methodologies mentioned in the report examine the critical vendors by considering their contribution to the global market. Furthermore, the report offers an in-depth insight into leading players’ performance based on revenue generation and client requirements. Also, the research report reveals